PubMed İndeksli Yayınlar Koleksiyonu by Institution Author "Sevindik, Ömür Gökmen"
Now showing items 1-17 of 17
-
Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri (NLM (Medline), 2022)Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly ... -
The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma
Solmaz, Şerife; Uzun, Özcan; Sevindik, Ömür Gökmen; Demirkan, Fatih; Özcan, Mehmet Ali; Özsan, Güner Hayri; Alacacıoğlu, İnci (John Wiley and Sons Inc, 2023)Introduction In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie-Salmon classification and the international staging system (ISS) that takes the serum ss2 microglobulin ... -
Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience
Kılıç Güneş, Ebru; Yiğit Kaya, Süreyya; Yaman, Fatih; Yeniay, Mustafa Kemal; Vural, Kurtuluş; Cömert, Melda; Sevindik, Ömür Gökmen; Andıç, Neslihan; Dağdaş, Simten; Nizam Özen, İlknur; Kaynar, Leylagül; Yavaşoğlu, Filiz; Özet, Gülsüm; Karakuş, Volkan; Aylı, Meltem (2024)Introduction: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this ... -
First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Lippincot Williams & Wilkins, 2022)Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can ... -
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
Doğu, Mehmet Hilmi; Tekgündüz, Ali İrfan Emre; Deveci, Burak; Korkmaz, Gülten; Cömert, Melda; Sevindik, Ömür Gökmen; Yokuş, Osman; Serin, İstemi (Mattioli 1885, 2023)Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ... -
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
Birtaş Ateşoğlu, Elif; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Ferhanoğlu, Burhan (Wiley, 2023)Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion ... -
Inherited transmission of the CSF3R T618I mutation: A familial report
Serin, istemi; Cinli, Tahir Alper; Tunç, Sertaç; Kaynar, Leylagül; Sevindik, Ömür Gökmen; Yokuş, Osman (Springer, 2023)To the editor, Chronic neutrophilic leukemia (CNL) is a rare, break cluster region-Abelson 1 (BCR-ABL1) negative myeloproliferative neoplasm, which is characterized by mature neutrophilic proliferation with neutrophilic ... -
Pegaspargase, venetoclax, and nelarabine: A successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient
Yiğit Kaya, Süreyya; Bektaş, Şebnem; Aşkın, Abdullah Emre; Balık Aydın, Berrin; Mutlu, Yaşa Gül; Sevindik, Ömür Gökmen (Springer, 2023)... -
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
Serin, İstemi; Sevindik, Ömür Gökmen; Balık Aydın, Berrin; Melek, Elif; Mutlu, Yaşa Gül; Bilgen, Hülya; Beköz, Hüseyin; Kaynar, Leylagül (Elsevier Ltd, 2023)Plerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and ... -
Prognostic factors and intensive care outcome in post-transplant phase of hematopoietic stem cell transplantation intensive care outcome in hematopoietic stem cell transplantation
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Erdoğan, Cem; Kızılaslan, Deniz; Beköz, Hüseyin Saffet; Gemici, Aliihsan; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Springer India, 2023)Introduction To identify new clinical and biologic parameters associated with short-term survival in allogeneic or autologous hematopoietic stem cell transplantation (HSCT) patients who were admitted to the intensive care ... -
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
Mutlu, Yaşa Gül; Yiğit Kaya, Süreyya; Maral, Senem; Melek, Elif; Başlar, Zafer; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Frontiers Media SA, 2023)Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific ... -
Should core needle lymph node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up of lymphomas?
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Çakır, Aslı; Canöz, Özlem; Erol, Cengiz; Sevindik, Ömür Gökmen (AVES, 2023)Objective: Surgical excisional biopsy is accepted as the standard of care approach in the diagnosis of lymphomas. Financial issues related to the increased cost and the invasive nature of the procedure forced physicians ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Yiğit Kaya, Süreyya; Mutlu, Yaşa Gül; Malkan, Ümit Yavuz; Mehtap, Özgür; Keklik Karadağ, Fatma; Korkmaz, Gülten; Elverdi, Tuğrul; Saydam, Güray; Özet, Gülsüm; Ar, Muhlis Cem; Melek, Elif; Maral, Senem; Kaynar, Leylagül; Sevindik, Ömür Gökmen (2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ... -
Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
Karakuş, Volkan; Maral, Senem; Kaya, Egemen; Gemici, Aliihsan; Dere, Yelda; Sevindik, Ömür Gökmen (Kare Publishing, 2022)OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of ... -
To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
Sevindik, Ömür Gökmen; Mergen, Mahmut; Mergen, Sena; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Springer Science and Business Media Deutschland GmbH, 2022)Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. ... -
Tocilizumab treatment in severe COVID-19: A multicenter retrospective study with matched controls
Mert, Ali; Vahaboğlu, Haluk; Arslan, Ferhat; Batirel, Ayşe; Saraçoğlu, Kemal Tolga; Baştuğ, Aliye; Çağatay, Atahan; Irmak, İlim; Telli Dizman, Gülçin; Ertenli, İhsan; Altunal, Lütfiye Nilsun; Ertürk Şengel, Buket; Bayram, Mehmet; Omma, Ahmet; Amikishiyev, Shirkhan; Aypak, Adalet; Bes, Cemal; Bölükçü, Sibel; İçten, Sacit; Topeli, Arzu; Bektaş, Murat; Arslan, Birsen Yiğit; Öztürk, Sinan; Çomoğlu, Şenol; Aydın, Selda; Küçükşahin, Orhan; İçaçan, Ozan Cemal; İnce, Burak; Aghamuradov, Sarvan; Yalçın Mutlu, Melek; Şimşek, Funda; Emre, Salih; Üstün, Cemal; Ergen, Pınar; Aydın, Özlem; Koç, Meliha Meriç; Sevindik, Ömür Gökmen; Odabaşı, Zekaver; Korten, Volkan; Bodur, Hürrem; Güner, Rahmet; Ünal, Serhat; Koçak, Mehmet; Gül, Ahmet (Springer Heidelberg, 2022)Coronavirus disease-2019 (COVID-19) associated pneumonia may progress into acute respiratory distress syndrome (ARDS). Some patients develop features of macrophage activation syndrome (MAS). Elevated levels of IL-6 were ...